- Verified Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- Mouse bone marrow mast cells
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
- Preparation
- The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421? under optimal conditions.
- Concentration
- Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
SB - Reported in the literature, not verified in house
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Brilliant Violet 421? excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421? is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet?.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. - Excitation Laser
- Violet Laser (405 nm)
- Application Notes
Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemistry of acetone fixed frozen sections2, and spatial biology (IBEX)5,6. The 2B8 antibody does not block c-Kit activity.
- Additional Product Notes
Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
- Application References
(PubMed link indicates BioLegend citation) -
- Ikuta K, et al. 1992. P. Natl. Acad. Sci. USA 89:1502. (FC)
- Podd BS, et al. 2006. J. Immunol. 176:6532. PubMed (IHC)
- Bachelet I, et al. 2008. J. Immunol. 180:6064. PubMed (FC)
- Charles N, et al. 2010. Nat. Med. 16:701. PubMed (FC)
- Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
- Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
- Product Citations
-
- Tan J, et al. 2021. iScience. 24(8):102835. PubMed
- Hutter K, et al. 2022. Front Immunol. 13:967914. PubMed
- Sch?nberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
- Bowers E, et al. 2018. Nat Med. 24:95. PubMed
- Liu L, et al. 2022. Cancers (Basel). 14:. PubMed
- Thiele K, et al. 2015. Am J Pathol. Available online 5 August 2015. PubMed
- Wu W, et al. 2014. Proc Natl Acad Sci U S A. 111:4221. PubMed
- Nakamura‐Ishizu A et al. 2018. Cell reports. 25(7):1772-1785 . PubMed
- Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
- Emg?rd J, et al. 2018. Immunity. 143:419. PubMed
- Carpenter RS, et al. 2020. Nat Commun. 3.029166667. PubMed
- Tyrkalska SD, et al. 2019. Immunity. 51:50. PubMed
- Derecka M, et al. 2020. Nat Immunol. 261:21. PubMed
- Siamishi I, et al. 2020. Cell Reports. 31(11):107756. PubMed
- Pinho S, et al. 2022. Nat Cell Biol. 24:290. PubMed
- Pinho S et al. 2018. Developmental cell. 44(5):634-641 . PubMed
- Philip E Boulais et al. 2018. Immunity. 49(4):627-639 . PubMed
- Wei Q, et al. 2020. Dev Cell. 53:503. PubMed
- Schuler F, et al. 2017. Nat Commun. . 10.1038/s41467-017-01850-4. PubMed
- Celik H, et al. 2018. Cancer Cell. 34:741. PubMed
- Hoffmann J, et al. 2021. Nat Commun. 12:3964. PubMed
- Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
- Gao X, et al. 2021. Nature. 589:591. PubMed
- Lefkopoulos S, et al. 2020. Immunity. 53(5):934-951.e9. PubMed
- Iwanami N, et al. 2020. iScience. 23:101260. PubMed
- Aryal B, et al. 2016. Nat Commun. 7:12313. PubMed
- Boulch M, et al. 2021. Sci Immunol. 6:. PubMed
- Gross KM, et al. 2019. Cell Rep. 28:394. PubMed
- Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
- Strattan E, et al. 2020. Frontiers in Immunology. 2.131944444. PubMed
- Tan DQ, et al. 2019. Cell Rep. 26:2316. PubMed
- Abdel Malik R, et al. 2017. Circ Res. 120:99. PubMed
- RRID
- AB_10898120 (BioLegend Cat. No. 105827) AB_11204256 (BioLegend Cat. No. 105828)
